公开(公告)号：US20180291079A1

公开(公告)日：2018-10-11

申请号：US15575707

申请日：2016-05-20

Applicant: Cellectis

Inventor： Julianne SMITH ,  Cècile SCHIFFER-MANNIOUI

IPC: C07K14/725 ,  C07K14/705 ,  C07K14/735 ,  C07K16/30 ,  C12N5/0783

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating solid tumors such as melanomas, carcinomas or liquid tumor such as T-cell lymphoblastic leukemia.

公开(公告)号：US10087453B2

公开(公告)日：2018-10-02

申请号：US14899107

申请日：2014-06-25

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Fayza Daboussi ,  David Sourdive ,  Jean-Charles Epinat

IPC: C12N15/82 ,  C12P7/64 ,  C12N9/16 ,  C12N9/12 ,  C12N9/10 ,  C12N9/02 ,  C12N9/04 ,  C12N15/79

Abstract: The invention provides engineered diatoms and methods of producing oil using diatoms. The invention also provides methods of modifying the lipids quantity and/or quality produced by diatom organisms through genome engineering. Also provided are oils, fuels, oleochemicals, chemical precursors, and other compounds manufactured from such modified diatoms.

公开(公告)号：US20180201901A1

公开(公告)日：2018-07-19

申请号：US15118801

申请日：2015-02-13

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  Laurent POIROT

IPC: C12N5/0783 ,  A61P35/00 ,  A61P35/02 ,  A61K35/17

Abstract: Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CS1 or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.

公开(公告)号：US20180134795A1

公开(公告)日：2018-05-17

申请号：US15314337

申请日：2015-06-17

Applicant: CELLECTIS

Inventor： Roman GALETTO

IPC: C07K16/28 ,  C07K14/735 ,  C07K14/705 ,  C12N15/85 ,  A61K35/17

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K35/26 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/70503 ,  C07K14/70517 ,  C07K14/70535 ,  C07K2319/03 ,  C12N15/85

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen CD123. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen CD123. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially leukemia.

公开(公告)号：US09944702B2

公开(公告)日：2018-04-17

申请号：US15301686

申请日：2015-04-02

Applicant: CELLECTIS

Inventor： Roman Galetto

IPC: C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K14/7051 ,  C07K14/70517 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/03

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD33 monoclonal antibody, conferring specific immunity against CD33 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.

公开(公告)号：US20180002435A1

公开(公告)日：2018-01-04

申请号：US15546630

申请日：2016-01-25

Applicant: Cellectis ,  RINAT NEUROSCIENCE CORPORATION

Inventor： Barbara Johnson SASU ,  Arvind RAJPAL ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Julien VALTON

IPC: C07K16/28 ,  C07K14/705 ,  G01N15/10 ,  G01N15/14 ,  C12N5/0783 ,  C07K14/725 ,  G01N15/00

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2510/00 ,  G01N15/1031 ,  G01N15/14 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/1081 ,  G01N2015/149

Abstract: A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.

公开(公告)号：US20180002427A1

公开(公告)日：2018-01-04

申请号：US15546619

申请日：2016-01-25

Applicant: CELLECTIS

Inventor： Julianne SMITH ,  Julien VALTON ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Arvind RAJPAL ,  Barbra Johnson SASU

IPC: C07K16/28 ,  C12N5/00 ,  C07K16/30 ,  A61K39/00 ,  A61K35/17 ,  C12N5/0783 ,  C07K14/725

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2510/00 ,  G01N15/1031 ,  G01N15/14 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/1081 ,  G01N2015/149

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen CLL1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen CLL1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially leukemia.

公开(公告)号：US20170183413A1

公开(公告)日：2017-06-29

申请号：US15126540

申请日：2015-03-19

Applicant: CELLECTIS

Inventor： Roman GALETTO

IPC: C07K16/28 ,  C07K14/725

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K14/7051 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/30

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.

公开(公告)号：US20170081672A1

公开(公告)日：2017-03-23

申请号：US15056544

申请日：2016-02-29

Applicant: CELLECTIS

Inventor： Thomas Stoddard ,  Song Luo

IPC: C12N15/52 ,  A01H4/00 ,  C12N9/22

CPC classification number: C12N15/52 ,  A01H4/008 ,  C12N9/22 ,  C12N15/8241 ,  C12N2840/10 ,  C12Y301/00

Abstract: Materials and methods for genome engineering through transient expression of a targeted nuclease are described herein. For example, the methods described herein can include introducing into a cell a messenger RNA (mRNA) that encodes a nuclease targeted to a selected sequence within the cell, where the stability of the mRNA is modified by the addition of untranslated regions (UTRs).

公开(公告)号：US20160312233A1

公开(公告)日：2016-10-27

申请号：US15103751

申请日：2014-12-12

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  Fayza DABOUSSI

IPC: C12N15/79 ,  C12N15/90 ,  C12N9/22 ,  C12N15/10

CPC classification number: C12N15/79 ,  C12N9/22 ,  C12N15/102 ,  C12N15/8209 ,  C12N15/821 ,  C12N15/8213 ,  C12N15/902 ,  C12N2800/80 ,  C12Y301/00

Abstract: The invention relates to a method to select transformed cells. In particular, the present invention relates to the use of a nuclease engineered to inactivate selectable marker which confers cell resistance to a toxic compound. The present invention relates to methods of modifying genome of a cell, preferably an algal cell comprising the present selection step. The present invention also relates to specific engineered nucleases, polynucleotides, vectors encoding thereof, kits and isolated cells comprising said nuclease.

Abstract translation: 本发明涉及一种选择转化细胞的方法。 特别地，本发明涉及工程化的核酸酶在使有毒化合物赋予细胞耐药性的选择性标记失活的用途。 本发明涉及修饰细胞基因组的方法，所述方法优选包含本选择步骤的藻细胞。 本发明还涉及特异性工程化核酸酶，多核苷酸，编码它们的载体，试剂盒和包含所述核酸酶的分离的细胞。